Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans (BMS-LyTrans)
|ClinicalTrials.gov Identifier: NCT01287923|
Recruitment Status : Completed
First Posted : February 2, 2011
Last Update Posted : April 10, 2018
|Condition or disease|
Two complementary approaches will be followed, one at the transcriptomic level for confirmation of diagnostic biomarkers and to assess for predictive biomarkers. The other one concern biologic studies to validate our biomarkers at the tissue level. Our project will be organized around 4 workpackages (WP), each of them includes tasks with a specific schedule & predefined deliverables. The first one concerns the general management, data warehouse, collections and different administrative and preanalytic issues. The 3 other WPs are scientific. We are first going to validate a 30-gene list, candidate diagnostic biomarkers, by qRT-PCR on: *) an independent set of DLBCLs compared to matched healthy blood donors (sensitivity assessment) and, **) on a series of low tumor burden DLBCLs, mantle cell lymphomas and non-malignant inflammatory disease constituted by patients with a septic shock (specificity assessment). All this latter collections are already available and ready to use. Secondly, we will complete our series of 89 hybridized patients on AFFY WholeExon microarrays by 60 supplementary and available samples in order to assess for molecular predictor of patient outcome. This question will be address based on the 3-year and 5-year as well, EFS (Event Free Survivor). All the clinical data are available through the GOELAMS eCRF. Since we dispose of a 31 probesets, 30 single genes, signature for the DLBCL diagnosis that involves 9 genes related to the myeloid compartment including 6 genes involved directly or not to the Myeloid-Derived Cell Suppression (MDSC) process, 20 genes described in the context of the cancer and, 11 genes connected to endothelial cells, we decided to explore by flow cytometry blood circulating cells. We will look for myeloid populations & subpopulations, endothelial cells and microparticles. The goal is the identification of specific MDSC perturbations, angiogenic abnormalities and functional impacts on the immune response in the context of the cancer.
We expect by our work to drive both basic science and clinical implications. On the scientific level, blood carries molecular and cellular components involved in tumor-host interactions. Our project should bring a deeper understanding in the immunological response that takes place in the blood compartment. This immunological response will be characterized on a molecular, cellular and functional level. On a clinical point of view, it may bring a new prognostic model in DLBCL. As blood is easily accessible, we expect it to be easily implemented in clinical practice and to allow the design of new clinical trials stratified on tumor biology features. It may also become a new way to monitor DLBCL's response to treatment. Furthermore, this project will provide a large amount of molecular data that can be easily connected with other ongoing GOELAMS studies. Valorisation of our findings will also be serious issue since our project is highly original and valuable.
|Study Type :||Observational|
|Actual Enrollment :||326 participants|
|Official Title:||Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans|
|Actual Study Start Date :||February 21, 2011|
|Actual Primary Completion Date :||June 8, 2017|
|Actual Study Completion Date :||September 1, 2017|
DLBCL patients included 075-GOELAMS trial or 075-like patient.
Blood donors from the EFS (French Blood Bank) of Rennes.
septic patients included at the Rennes University Hospital.
DLBCL in completed remission
DLBCL patients from the 075 GOELAMS study in completed remission.
- Research for cancer-related biomarkers [ Time Frame: 3 years ]In this project we propose two complementary approaches with a first one orientated to the continuum of our current findings based on genes differentially expressed in blood between DLBCL patients and healthy people and a second one which takes in account the power and originality of our 075 GOELAMS cohort and will be focused on the research of predictive signatures of the DLBCL. We will go beyond the sole transcriptomic approach and also look for relevant cell biology clues.
- Sensitivity & specificity of the identified molecular signature in the DLBCL diagnosis context [ Time Frame: 3 years ]Sensitivity & specificity of the identified molecular signature in the DLBCL
- Identify a prognostic whole blood RNA signature related to aggressive DLBCL [ Time Frame: 3 years ]Identify a prognostic whole blood RNA signature related to aggressive DLBCL
- Proportion and phenotypic characteristics of circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL [ Time Frame: 3 years ]Proportion and phenotypic characteristics of circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL
- Immune functions of these circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL [ Time Frame: 3 years ]Immune functions of these circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL
Biospecimen Retention: Samples With DNA
For this study, 4 newly included cohorts are necesseray :
- 100 new DLBCL patients are necessary. The blood will be taken at the diagnosis for DLBCL patients included 075-GOELAMS trial or 075-like patient.
- 100 healthy blood donors. This cohort of matched for sex & gender will be constituted at the EFS (French Blood Bank) of Rennes.
- 100 septic patients included at the Rennes University Hospital.
- 100 075-like DLBCL patients in completed remission.
This project will also used already available blood collections: 2) Mantle cell lymphoma, 3) localized DLBCL and septic shock. Paraffin blocks of patient 075-trial DLBCLs are in the GOELAMSthèque bank localized in the Pathology Department Hôtel Dieu, Paris supervised by Pr Diane Damotte. Tissue Microarrays and complete paraffin blocks as well as some -80° tumors are already available.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01287923
|Amiens University Hospital|
|Amiens, France, 80054|
|Angers University Hospital|
|Angers, France, MD|
|Victor Dupouy Hospital|
|Argenteuil, France, 95100|
|Cesson-Sévigné, France, 35576|
|La Roche-sur-Yon Hospital|
|La Roche-sur-Yon, France, 85025|
|Lille University Hospital|
|Lille, France, 59037|
|Lorient, France, 56100|
|Nantes University Hospital (Hôtel-Dieu)|
|Nantes, France, 44093|
|Bordeaux University Hospital ( Haut-Lévêque Hospital)|
|Pessac, France, 33604|
|Poitiers University Hospital|
|Poitiers, France, MD|
|Rennes, France, 35000|
|Rennes University Hospital|
|Rennes, France, 35000|
|Saint-Brieuc, France, 22000|
|Saint-Malo, France, 35400|
|Loire Cancer Institute|
|Saint-Priest-en-Jarez, France, 42271|
|Toulouse University Hospital|
|Toulouse, France, 35059|
|Vannes, France, 56000|
|Principal Investigator:||Thierry Fest, MD||Rennes University Hospital|